1471985-92-8
Chemical Structure
Vandortuzumab vedotin
Synonym(s): DSTP 3086S; RG 7450; MSTP2109A
- CAS No.: 1471985-92-8
- Molecular Weight:N/A
IUPAC Name: 3-bromo-2-(methylamino)phenol
SMILES: [Vandortuzumab vedotin]
Biological Activity: Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug conjugate (ADC) targeting STEAP1. Vandortuzumab vedotin binds to STEAP1 and triggers internalization, mediating the intracellular release of MMAE, which inhibits microtubule polymerization, thereby inhibiting cell division and inducing cell death. Vandortuzumab vedotin shows antitumor activity in prostate cancer xenograft tumors. Vandortuzumab vedotin can be used in research on metastatic castration-resistant prostate cancer and prostate cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vandortuzumab vedotin | 99.52% | Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug conjugate (ADC) targeting STEAP1. Vandortuzumab vedotin binds to STEAP1 and triggers internalization, mediating the intracellular release of MMAE, which inhibits microtubule polymerization, thereby inhibiting cell division and inducing cell death. Vandortuzumab vedotin shows antitumor activity in prostate cancer xenograft tumors. Vandortuzumab vedotin can be used in research on metastatic castration-resistant prostate cancer and prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Danila DC, et al. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Dec 20;37(36):3518-3527. [Content Brief]
- [2]. Chaudhry GE, et al. Cancer and apoptosis: The apoptotic activity of plant and marine natural products and their potential as targeted cancer therapeutics. Frontiers in pharmacology. 2022;13:842376. [Content Brief]
